Mounjaro is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes and weight management in the UK
In a 2025 study of 559 Blue Sky MD patients, the combined program averaged ~13% body-weight loss in 12 weeks more than medication alone
Opportunities Ahead As hypergrowth slows, localization is fueling global expansion see Australias The Yard and Fitstop, OTF in the UK, and European brands PureGym and RSG Group pursuing North America
Epidemiological research has been conducted to examine the potential link between the prescription of TZDs and the reduced risks of AD [28, 29] and PD [30, 31], and studies have explored their anti-inflammatory and neuroprotective effects [32]
e Metabolic risk, poor glycemic control or weight loss desired
NAD+ powers energy and repair : Functions as cellular battery for energy production, DNA repair, and cognitive enhancement, with benefits lasting 24-72 hours via IV therapy